TG THROMBOGENICS
LIVE

Serial Number

79093385

Owner

ThromboGenics NV

Attorney

Thomas J. Mango

Filing Date

Nov 30, 2010

Add to watchlist:

No watchlists yet
View on USPTO

TG THROMBOGENICS Trademark

Serial Number: 79093385 • Registration: 4047607

TG THROMBOGENICS is a trademark filed by ThromboGenics NV on November 30, 2010. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

ThromboGenics NV (13 trademarks)

Gaston Geenslaan 1
Heverlee 3001 , BE

Entity Type: 99

Oxurion NV (10 trademarks)

Gaston Geenslaan 1

Entity Type: 32

Trademark Details

Filing Date

November 30, 2010

Registration Date

November 1, 2011

Published for Opposition

August 16, 2011

Cancellation Date

May 13, 2022

Goods & Services

Chemical preparations and substances for use in the manufacture of pharmaceuticals

Pharmaceutical preparations for treatment of diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; veterinary preparations for treatment of diseases and disorders in mammalians, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; sanitary preparations for medical purposes; dietetic foods adapted for medical use, food for babies; medical plasters; material for stopping teeth, dental wax; disinfectants for medical instruments, for hygienic purposes, and for use in medical surgery procedures; preparations for destroying vermin; fungicides, herbicides; biopharmaceutical preparations, namely, anticoagulants, anti angiogenic drugs, anticancer drugs, cardiovascular drugs, protease enzymes, protease inhibitors, antibodies, plasmins, truncated plasmins, microplasmins, plasminogens, truncated plasminogens, microplasminogens, plasminogen activators, staphylokinases for the treatment diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; diagnostic medical reagents, chemicals and biological materials, namely, antigen and diagnostic kits consisting primarily of monoclonal and/or polyclonal antibodies, buffers, and reagents for medical laboratory use in disease testing

Medical services; veterinary services; medical, veterinary and pharmaceutical advisory and consultancy services; medical services, namely, therapeutic, prognostic and diagnostic testing services

Scientific and technological services, namely, scientific research and design of new products in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention, and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; industrial analysis and product research services in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; pharmaceutical, biopharmaceutical, medical, biomedical, biological, biochemical, toxicological and clinical research and product development of diagnostic tests and kits, biopharmaceutical preparations and drugs, and medicines; biopharmaceutical product evaluation; biological, biochemical, pharmaceutical, medical, toxicological and clinical research, scientific research for medical purposes in the treatment of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer diseases and disorders; development services in the field of new biopharmaceutical drugs, preparations and medicines for ophthalmic, vascular and cancer pathologies

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Feb 26, 2026 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jan 8, 2026 NREP
TOTAL INVALIDATION PROCESSED BY THE IB
Apr 11, 2023 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Mar 1, 2023 INTS
INVALIDATION PROCESSED
Mar 1, 2023 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 13, 2023 INTR
CANCELLED SECTION 71
May 13, 2022 C71T
INTERNATIONAL REGISTRATION RENEWED
Dec 17, 2020 RNWL
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Nov 1, 2020 REM4
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 13, 2019 ADCH
PARTIAL INVALIDATION PROCESSED BY THE IB
Mar 8, 2019 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jan 26, 2019 INPS
INVALIDATION PROCESSED
Jan 26, 2019 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 11, 2019 INPR
NEW REPRESENTATIVE AT IB RECEIVED
Sep 28, 2018 NREP
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
May 11, 2018 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
May 11, 2018 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 11, 2018 APRE
TEAS SECTION 71 RECEIVED
May 1, 2018 ES71
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 28, 2012 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 8, 2012 FICS
FINAL DISPOSITION PROCESSED
Jun 8, 2012 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 1, 2012 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 1, 2011 R.PR
PUBLISHED FOR OPPOSITION
Aug 16, 2011 PUBO
NOTICE OF PUBLICATION
Jul 27, 2011 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 13, 2011 PREV
ASSIGNED TO LIE
Jul 12, 2011 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 18, 2011 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 17, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 17, 2011 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 17, 2011 TROA
REFUSAL PROCESSED BY IB
Apr 9, 2011 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 22, 2011 RFCS
REFUSAL PROCESSED BY MPU
Mar 22, 2011 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 19, 2011 RFCR
NON-FINAL ACTION WRITTEN
Mar 18, 2011 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 12, 2011 MAFR
ASSIGNED TO EXAMINER
Mar 8, 2011 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 8, 2011 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 4, 2011 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 3, 2011 REPR